New name for merged company
American Pharmaceutical Partners, which produces many multisourceinjectable drugs for cancer, critical care, and infection control,has merged with American BioScience to form Abraxis BioScience, LosAngeles. A major drug in its portfolio is the breast cancer drugAbraxane for Injectable Suspension (paclitaxel protein-boundparticles for injectable suspension) (albumin-bound).
American Pharmaceutical Partners, which produces many multisource injectable drugs for cancer, critical care, and infection control, has merged with American BioScience to form Abraxis BioScience, Los Angeles. A major drug in its portfolio is the breast cancer drug Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
To go to the Drug Topics homepage, click here http://www.drugtopics.com.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
